Drug Trial Radar · NCT02694744
Patiromer With or Without Food for the Treatment of Hyperkalemia
Last checked: Nov 20, 2026Latest source record: May 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
114
Actual
Start
Feb 2016
Primary completion
Jul 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- Relypsa, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high potassium in the blood).
Conditions
- Hyperkalemia
Interventions
patiromerDrug
8.4 g/day starting dose, administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Serum Potassium in the Target Range (3.8 - 5.0 mEq/L) at Either Week 3 or Week 4Time frame: 21 to 28 Days
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Investigator Site 12
Fountain Valley, California
Investigator Site 11
Huntington Beach, California
Investigator Site 38
Palm Springs, California
Investigator Site 20
Riverside, California
Investigator Site 21
San Dimas, California
Investigator Site 24
Denver, Colorado
Investigator Site 30
Edgewater, Florida
Investigator Site 10
Hialeah, Florida
Investigator Site 13
Hollywood, Florida
Investigator Site 17
Lauderdale Lakes, Florida
Investigator Site 16
Lauderdale Lakes, Florida
Investigator Site 15
Miami, Florida
Investigator Site 43
Miami, Florida
Investigator Site 18
Pembroke Pines, Florida
Investigator Site 27
Tampa, Florida
Investigator Site 44
Meridian, Idaho
Investigator Site 39
Aurora, Illinois
Investigator Site 23
Flint, Michigan
Investigator Site 34
Kansas City, Missouri
Investigator Site 41
Las Vegas, Nevada
Investigator Site 37
Flushing, New York
Investigator Site 36
Norman, Oklahoma
Investigator Site 40
Jackson, Tennessee
Investigator Site 33
Dallas, Texas
Investigator Site 26
San Antonio, Texas
Investigator Site 29
San Antonio, Texas
Investigator Site 28
San Antonio, Texas
Investigator Site 25
San Antonio, Texas
Investigator Site 22
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.